Chemomab Therapeutics Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CMMB | EDSA | AGMB | BYSI | CRIS | CHRS | |
|---|---|---|---|---|---|---|
| Market cap | 9.90M | 29.32M | 337.35M | 27.92M | 7.41M | 131.36M |
| P/E (TTM) | — | — | — | — | 0.8 | — |
| Forward P/E | -41.0 | — | -3.4 | -1.4 | -0.2 | -1.3 |
| Price/book | 1.0 | 52.9 | 2.7 | -0.8 | 0.5 | 2.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −55.81% | +27.65% | −53.24% | −68.15% | −97.50% | −42.95% |
| Today | +4.24% | −4.82% | 0.00% | +9.34% | +55.48% | +5.54% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CMMB news ›Hannah Wardill: Is Chemobrain a Central Symptom of Systemic Pathology?
“Is chemobrain a central symptom of systemic pathology? This is a question we need to be asking more often in cancer survivorship research. For too long, chemotherapy-related cognitive impairment (CRCI) has been approached primarily as a…
Chemomab Therapeutics and Scipher Medicine Announce SEC Registration Statement on Form S-4 Is Effective
Special meeting of Chemomab shareholders to vote on the proposed merger scheduled for December 4, 2026 The Registration Statement and the Proxy Statement are available at www.sec.gov and also at the Investors page on the Chemomab website…
OMass Therapeutics Announces $310 Million Series C Financing to Advance Portfolio of Small Molecule Therapeutics in Endocrinology and Immunology – Omass
Financing co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings, with strong participation from additional new and existing investors Proceeds to advance MC2 receptor antagonist OMS1620 through Phase 2 development…
SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
SAB Biotherapeutics, Inc. a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin for type 1 diabetes and other autoimmune diseases, today announced that members of its management team will…
Amplia Showcases FAK Inhibitor Progress at CG Drug and Device Conference
Amplia Therapeutics ( (AU:ATX) ) has provided an announcement. Amplia Therapeutics has released CEO Chris Burns’ presentation delivered at the Canaccord Genuity Drug and Device Conference 2026 in Noosa, highlighting progress across its…
anti-TCR Vb6/Vb10/IL-2 antibody fusion protein STAR0602
Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes links to find associated clinical trials. National Cancer Institute at the National…
Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026
The Manila Times Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026 REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq
Inhibrx Announces Participation in Upcoming Scientific Conferences
Oct 13, 2026, 16:00 ET SAN DIEGO, Oct. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic…
MINT study results strengthen real‑world evidence for mogamulizumab
by John Pinching | 13th Oct 2026 | News Kyowa Kirin International has announced final results from the German MINT study evaluating mogamulizumab in patients with MF and SS. Presented at the EORTC‑CLTG Annual Meeting 2026, the findings…
Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference
Coya Therapeutics (COYA) will participate in a panel discussion at Chardan's 10th Annual Healthcare Conference on October 20 in New York. Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- stocktitan.net3
- globenewswire.com1
- investingnews.com1
- manilatimes.net1
- markets.businessinsider.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.